Management of Enzalutamide Related Adverse Events for Castration Resistant Prostate Cancer by Patient Reported Outcomes

Castration Resistant ◽

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30898-2 ◽

2019 ◽

Vol 20 (4) ◽

pp. 556-569 ◽

Cited By ~ 30

Author(s):

Bertrand Tombal ◽

Fred Saad ◽

David Penson ◽

Maha Hussain ◽

Cora N Sternberg ◽

...

Keyword(s):

Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

PD16-08 EFFECT OF CABAZITAXEL VS ABIRATERONE OR ENZALUTAMIDE ON PATIENT-REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

The Journal of Urology ◽

10.1097/ju.0000000000000859.08 ◽

2020 ◽

Vol 203 ◽

pp. e366

Author(s):

Gero Kramer* ◽

Cora N. Sternberg ◽

Karim Fizazi ◽

Bertrand Tombal ◽

Jean-Christophe Eymard ◽

...

Keyword(s):

Prostate Cancer ◽

Castration Resistant ◽

Patient Reported Outcomes in Metastatic Castration-Resistant Prostate Cancer

Value in Health ◽

10.1016/j.jval.2013.08.561 ◽

2013 ◽

Vol 16 (7) ◽

pp. A421

Author(s):

S. Aggarwal ◽

J. Segal ◽

S. Kumar

Keyword(s):

Prostate Cancer ◽

Castration Resistant ◽

MP52-20 PATIENT REPORTED OUTCOMES (PROS) IN SPARTAN, A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY OF APALUTAMIDE (APA) PLUS ANDROGEN DEPRIVATION THERAPY (ADT) VS PLACEBO PLUS ADT IN MEN WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)

The Journal of Urology ◽

10.1016/j.juro.2018.02.1671 ◽

2018 ◽

Vol 199 (4S) ◽

Cited By ~ 1

Author(s):

Eric J. Small ◽

Fred Saad ◽

Boris A. Hadaschik ◽

Julie N. Graff ◽

Paul N. Mainwaring ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Randomized Study ◽

Androgen Deprivation ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Patient Reported Outcomes in Castration-Resistant Prostate Cancer

Value in Health ◽

10.1016/j.jval.2014.03.547 ◽

2014 ◽

Vol 17 (3) ◽

pp. A94

Author(s):

S. Aggarwal ◽

J. Segal

Keyword(s):

Prostate Cancer ◽

Castration Resistant ◽

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)

Journal of Patient-Reported Outcomes ◽

10.1186/s41687-018-0054-5 ◽

2018 ◽

Vol 2 (1) ◽

Cited By ~ 6

Author(s):

Joseph M. Unger ◽

Katherine Griffin ◽

Gary W. Donaldson ◽

Karen M. Baranowski ◽

Margorie J. Good ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase Iii ◽

Phase Iii Clinical Trial ◽

Castration Resistant ◽

PCN388 - PATIENT REPORTED OUTCOMES IN THE CASTRATION RESISTANT PROSTATE CANCER REGISTRY (PRO-CAPRI) IN THE NETHERLANDS

Value in Health ◽

10.1016/j.jval.2018.09.2849 ◽

2018 ◽

Vol 21 ◽

pp. S80

Author(s):

M. Kuppen ◽

H.M. Westgeest ◽

A. Van den Eertwegh ◽

R. Moorselaar ◽

N. Mehra ◽

...

Keyword(s):

Prostate Cancer ◽

The Netherlands ◽

Cancer Registry ◽

Castration Resistant ◽

Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study

European Urology ◽

10.1016/j.eururo.2019.09.019 ◽

2020 ◽

Vol 77 (3) ◽

pp. 380-387 ◽

Cited By ~ 5

Author(s):

Antoine Thiery-Vuillemin ◽

Mads Hvid Poulsen ◽

Edouard Lagneau ◽

Guillaume Ploussard ◽

Alison Birtle ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant ◽

Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302

Annals of Oncology ◽

10.1093/annonc/mdx759 ◽

2018 ◽

Vol 29 (2) ◽

pp. 392-397 ◽

Cited By ~ 14

Author(s):

D. Cella ◽

S. Traina ◽

T. Li ◽

K. Johnson ◽

K.F. Ho ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Outcomes ◽

Post Hoc Analysis ◽

Castration Resistant ◽

Patient Reported ◽

Post Hoc

Patient-reported outcomes in metastatic castration-resistant prostate cancer

Nature Reviews Clinical Oncology ◽

10.1038/nrclinonc.2016.100 ◽

2016 ◽

Vol 13 (10) ◽

pp. 643-650 ◽

Cited By ~ 14

Author(s):

Lesley Fallowfield ◽

Heather Payne ◽

Valerie Jenkins

Keyword(s):

Prostate Cancer ◽

Castration Resistant ◽